Week ahead: U:S. nonfarm payrolls, Global PMIs in the spotlight
All eyes over the coming week would be on the U.S. non-farm payrolls report for March.
Source: sharecast.com
Page 3 - Kitwave Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kitwave Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kitwave Group Today - Breaking & Trending Today
Kitwave buys Total Foodservice for GBP21 million
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ---------- Triple Point Energy Transition PLC - investment trust,...
Source: marketscreener.com
Investment Analysts' Price Target Changes for March 28th (AKBA, ALLY, AROC, ATEC, AXP, AXSM, BAC, BRZE, BWXT, CCL)
Investment Analysts’ price target changes for Thursday, March 28th: Akebia Therapeutics (NASDAQ:AKBA) had its price target raised by HC Wainwright from $5.00 to $6.00. The firm currently has a buy rating on the stock. Ally Financial (NYSE:ALLY) had its target price increased by Evercore ISI from $41.00 to $43.00. Evercore ISI currently has an in-line […]
Source: dailypolitical.com
Investment Analysts' Price Target Changes for March 28th (AKBA, ALLY, AROC, ATEC, AXP, AXSM, BAC, BRZE, BWXT, CCL)
Investment Analysts’ price target changes for Thursday, March 28th: Akebia Therapeutics (NASDAQ:AKBA) had its price target raised by HC Wainwright from $5.00 to $6.00. The firm currently has a buy rating on the stock. Ally Financial (NYSE:ALLY) had its target price increased by Evercore ISI from $41.00 to $43.00. Evercore ISI currently has an in-line […]
Source: tickerreport.com
Investment Analysts' Price Target Changes for March 28th (AKBA, ALLY, AROC, ATEC, AXP, AXSM, BAC, BRZE, BWXT, CCL)
Investment Analysts’ price target changes for Thursday, March 28th: Akebia Therapeutics (NASDAQ:AKBA) had its price target raised by HC Wainwright from $5.00 to $6.00. The firm currently has a buy rating on the stock. Ally Financial (NYSE:ALLY) had its target price increased by Evercore ISI from $41.00 to $43.00. Evercore ISI currently has an in-line […]
Source: wkrb13.com